The untreated human immunodeficiency virus (HIV), a lentivirus species that attacks immune
cells (CD4+ T cells), causes acquired immunodeficiency syndrome (AIDS). HIV-positive …

Background: The real-world impact on viral suppression of switching from non–dolutegravir-
based therapy to tenofovir/lamivudine/dolutegravir (TLD) is not thoroughly characterized in …

During the COVID-19 pandemic, HIV programs scaled up differentiated service delivery
(DSD) models for people living with HIV (PLHIV). We evaluated the effects of COVID-19 on …

Background: Despite the reduced human immunodeficiency virus (HIV) disease burden in
Nigeria and globally, the key populations (KPs) can be disproportionately burdened with HIV …

Background A key strategy for quality improvement is drug use evaluation, which looks at
the safe, appropriate use of medication principles. Tenofovir/Lamivudine/Dolutegravir (TLD …

There has been improvement in the control of HIV/AIDS in Nigeria. The 2018 national
prevalence was 1.4%, a decline from previous surveys. The gains are however not uniform; …

Virologic outcome is the assessment of an human immuno-deficiency virus (HIV)-positive
patient response antiretroviral therapy adherence using real-time polymerase chain reaction …

Background The dolutegravir-based antiretroviral regimen is the preferred first-line regimen
for the management of people living with human immunodeficiency virus in Nepal recently. It …

Essentially all HIV transmission is from people living with HIV who are not virally
suppressed. An HIV micro-epidemic control approach that differentiates treatment support …

Highly Active Anti-Retroviral Therapy (HAART) is the mainstay in the management of Human
Immunodeficiency Virus (HIV) infection. It is important to evaluate the efficacy of new drugs …